Sun Pharma secures NCLT approval for composite scheme

On October 8, 2025, Sun Pharmaceutical Industries Limited (Sun Pharma) announced that the National Company Law Tribunal (NCLT), Ahmedabad Bench, approved its Composite Scheme of Arrangement. The scheme, effective from April 1, 2023, involves the amalgamation of five wholly-owned subsidiary companies—Sun Pharmaceutical Medicare Limited, Green Eco Development Centre Limited, Faststone Mercantile Company Private Limited, Realstone Multitrade Private Limited, and Skisen Labs Private Limited—into Sun Pharma.

The NCLT's approval also covers the reclassification and transfer of Sun Pharma's General Reserve to Retained Earnings. The tribunal found the scheme beneficial to the companies and not detrimental to the interests of shareholders, creditors, or statutory authorities.

Statutory bodies, including the regional director, registrar of companies, and official liquidator, provided observations, which the petitioner companies addressed. The Income Tax Department noted an outstanding demand of Rs. 1,099,85,89,654 against Sun Pharma, which the company has undertaken to fulfill once finally confirmed. Additionally, legal and other expenses totaling Rs. 100,000 for the regional director and official liquidator are to be paid by Sun Pharma.